Literature DB >> 22176623

Pharmacogenetics of obsessive-compulsive disorders.

Eva J Brandl1, Daniel J Müller, Margaret A Richter.   

Abstract

Genetic factors have been shown to influence occurrence and severity of several psychiatric disorders and also to modulate outcome to drug treatment. Obsessive-compulsive disorder (OCD) is a severe psychiatric condition with clear genetic roots; there is also some evidence to suggest that genetic factors may impact on response to drug treatment. Typically between 40 and 60% of patients are deemed nonresponders to antidepressant medication and clinical factors have only been modestly correlated with treatment response. Thus, identification of biological factors which may relate to treatment response could be extremely valuable in improving clinical outcome. In this article, we briefly review previous work regarding clinical and demographical factors associated with drug response in OCD, then focus on recent findings regarding candidate genes which may influence drug response, including those in the serotonin system, brain-derived neurotrophic factor and the glutamate transporter gene. The cytochrome system may also be highly relevant to drug response. Thus far, relatively few studies regarding the pharmacogenetics of OCD have been published, and therefore further investigation with functional analyses and consideration of environmental factors are warranted to facilitate clinical use of pharmacogenetic findings in the future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22176623     DOI: 10.2217/pgs.11.133

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  11 in total

Review 1.  Pharmacological treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Michael H Bloch
Journal:  Psychiatr Clin North Am       Date:  2014-07-24

2.  Conditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomes.

Authors:  Geraldine T Petr; Yan Sun; Natalie M Frederick; Yun Zhou; Sameer C Dhamne; Mustafa Q Hameed; Clive Miranda; Edward A Bedoya; Kathryn D Fischer; Wencke Armsen; Jianlin Wang; Niels C Danbolt; Alexander Rotenberg; Chiye J Aoki; Paul A Rosenberg
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

3.  Facilitation of serotonin signaling by SSRIs is attenuated by social isolation.

Authors:  Elyse C Dankoski; Kara L Agster; Megan E Fox; Sheryl S Moy; R Mark Wightman
Journal:  Neuropsychopharmacology       Date:  2014-07-01       Impact factor: 7.853

4.  The Future of Obsessive-Compulsive Spectrum Disorders: A Research Perspective.

Authors:  T Vats; N A Fineberg; E Hollander
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 5.  Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Authors:  Katarzyna Drozda; Daniel J Müller; Jeffrey R Bishop
Journal:  Pharmacotherapy       Date:  2014-02       Impact factor: 4.705

Review 6.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 7.  Pharmacogenetics of Obsessive-Compulsive Disorder: An Evidence-Update.

Authors:  Gwyneth Zai
Journal:  Curr Top Behav Neurosci       Date:  2021

8.  Whole-genome association analysis of treatment response in obsessive-compulsive disorder.

Authors:  H Qin; J F Samuels; Y Wang; Y Zhu; M A Grados; M A Riddle; B D Greenberg; J A Knowles; A J Fyer; J T McCracken; D L Murphy; S A Rasmussen; B A Cullen; J Piacentini; D Geller; S E Stewart; D Pauls; O J Bienvenu; F S Goes; B Maher; A E Pulver; D Valle; C Lange; M Mattheisen; N C McLaughlin; K-Y Liang; E L Nurmi; K D Askland; G Nestadt; Y Y Shugart
Journal:  Mol Psychiatry       Date:  2015-03-31       Impact factor: 15.992

Review 9.  GABA and Glutamate Transporters in Brain.

Authors:  Yun Zhou; Niels Christian Danbolt
Journal:  Front Endocrinol (Lausanne)       Date:  2013-11-11       Impact factor: 5.555

Review 10.  Glutamate as a neurotransmitter in the healthy brain.

Authors:  Y Zhou; N C Danbolt
Journal:  J Neural Transm (Vienna)       Date:  2014-03-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.